Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
Induced splice modulation of pre-mRNAs shows promise to correct aberrant disease transcripts and restore functional protein and thus has therapeutic potential. Duchenne muscular dystrophy (DMD) results from mutations that disrupt the DMD gene open reading frame causing an absence of dystrophin prote...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826261420969295872 |
|---|---|
| author | Yin, H Saleh, A Betts, C Camelliti, P Seow, Y Ashraf, S Arzumanov, A Hammond, S Merritt, T Gait, M Wood, M |
| author_facet | Yin, H Saleh, A Betts, C Camelliti, P Seow, Y Ashraf, S Arzumanov, A Hammond, S Merritt, T Gait, M Wood, M |
| author_sort | Yin, H |
| collection | OXFORD |
| description | Induced splice modulation of pre-mRNAs shows promise to correct aberrant disease transcripts and restore functional protein and thus has therapeutic potential. Duchenne muscular dystrophy (DMD) results from mutations that disrupt the DMD gene open reading frame causing an absence of dystrophin protein. Antisense oligonucleotide (AO)-mediated exon skipping has been shown to restore functional dystrophin in mdx mice and DMD patients treated intramuscularly in two recent phase 1 clinical trials. Critical to the therapeutic success of AO-based treatment will be the ability to deliver AOs systemically to all affected tissues including the heart. Here, we report identification of a series of transduction peptides (Pip5) as AO conjugates for enhanced systemic and particularly cardiac delivery. One of the lead peptide-AO conjugates, Pip5e-AO, showed highly efficient exon skipping and dystrophin production in mdx mice with complete correction of the aberrant DMD transcript in heart, leading to >50% of the normal level of dystrophin in heart. Mechanistic studies indicated that the enhanced activity of Pip5e-phosphorodiamidate morpholino (PMO) is partly explained by more efficient nuclear delivery. Pip5 series derivatives therefore have significant potential for advancing the development of exon skipping therapies for DMD and may have application for enhanced cardiac delivery of other biotherapeutics. |
| first_indexed | 2024-03-06T19:21:10Z |
| format | Journal article |
| id | oxford-uuid:1a2340da-6b65-4d54-ab71-a95e10656828 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:21:10Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:1a2340da-6b65-4d54-ab71-a95e106568282022-03-26T10:53:08ZPip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1a2340da-6b65-4d54-ab71-a95e10656828EnglishSymplectic Elements at Oxford2011Yin, HSaleh, ABetts, CCamelliti, PSeow, YAshraf, SArzumanov, AHammond, SMerritt, TGait, MWood, MInduced splice modulation of pre-mRNAs shows promise to correct aberrant disease transcripts and restore functional protein and thus has therapeutic potential. Duchenne muscular dystrophy (DMD) results from mutations that disrupt the DMD gene open reading frame causing an absence of dystrophin protein. Antisense oligonucleotide (AO)-mediated exon skipping has been shown to restore functional dystrophin in mdx mice and DMD patients treated intramuscularly in two recent phase 1 clinical trials. Critical to the therapeutic success of AO-based treatment will be the ability to deliver AOs systemically to all affected tissues including the heart. Here, we report identification of a series of transduction peptides (Pip5) as AO conjugates for enhanced systemic and particularly cardiac delivery. One of the lead peptide-AO conjugates, Pip5e-AO, showed highly efficient exon skipping and dystrophin production in mdx mice with complete correction of the aberrant DMD transcript in heart, leading to >50% of the normal level of dystrophin in heart. Mechanistic studies indicated that the enhanced activity of Pip5e-phosphorodiamidate morpholino (PMO) is partly explained by more efficient nuclear delivery. Pip5 series derivatives therefore have significant potential for advancing the development of exon skipping therapies for DMD and may have application for enhanced cardiac delivery of other biotherapeutics. |
| spellingShingle | Yin, H Saleh, A Betts, C Camelliti, P Seow, Y Ashraf, S Arzumanov, A Hammond, S Merritt, T Gait, M Wood, M Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. |
| title | Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. |
| title_full | Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. |
| title_fullStr | Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. |
| title_full_unstemmed | Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. |
| title_short | Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. |
| title_sort | pip5 transduction peptides direct high efficiency oligonucleotide mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice |
| work_keys_str_mv | AT yinh pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT saleha pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT bettsc pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT camellitip pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT seowy pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT ashrafs pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT arzumanova pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT hammonds pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT merrittt pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT gaitm pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice AT woodm pip5transductionpeptidesdirecthighefficiencyoligonucleotidemediateddystrophinexonskippinginheartandphenotypiccorrectioninmdxmice |